USC’s Keck Medicine is conducting a new research to see if immunotherapy administered at home is equally effective as in a hospital. The treatment goal of...
The immunotherapy drug, durvalumab, has been the norm of care for patients with stage III non-little cell lung cancer(NSCLC) to further develop endurance, when recommended after...
New data indicate that, despite an increase in the prevalence of lung cancer screening, there are still significant disparities in screening rates among adults who are...
